Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elicio Therapeutics, Inc. (Nasdaq: ELTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Elicio is a clinical-stage biotechnology company developing AMP-based, off-the-shelf immunotherapies for mKRAS-driven and other cancers, and its filings offer detailed insight into this development strategy, financial position, and risk profile.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe Elicio’s clinical programs such as ELI-002 2P and 7P, the AMPLIFY-201 and AMPLIFY-7P trials in pancreatic and colorectal cancers, the broader AMP platform, and the company’s liquidity and operating expenses. Current reports on Form 8-K capture material events, including the release of clinical immunogenicity data, recommendations from the Independent Data Monitoring Committee for the Phase 2 AMPLIFY-7P study, publication of Phase 1 results in peer-reviewed journals, and the announcement of quarterly financial results.
Investors interested in insider activity can also look for Forms 3, 4 and 5, which disclose transactions by directors, officers and significant shareholders, where available. Proxy statements on Schedule 14A may provide information on governance matters and executive compensation related to Elicio’s leadership team and board.
On Stock Titan, Elicio’s SEC filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key sections related to ELI-002, the AMP platform, clinical trial milestones, and cash runway, and help explain complex disclosures in accessible language. This allows users to quickly identify important changes in Elicio’s clinical development plans, financial condition, and risk factors without reading every page of each filing.
Elicio Therapeutics, Inc. entered into an at-the-market stock sales program allowing it to issue and sell up to $100.0 million of common stock from time to time through B. Riley Securities, JonesTrading and Ladenburg Thalmann under a new Sales Agreement.
Sales will be made pursuant to an effective Form S-3 shelf registration, with the agents earning a 3.0% commission on gross proceeds. The company is not required to sell any shares and can terminate the arrangement on short notice.
Elicio also terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had allowed sales of up to $40.0 million of common stock, and confirmed there are no termination penalties and no further shares may be sold under that earlier program.
Elicio Therapeutics is offering up to $100,000,000 of common stock in an “at the market” (ATM) sales program. The company may sell shares from time to time through B. Riley Securities, JonesTrading or Ladenburg Thalmann under a March 16, 2026 Sales Agreement.
The Sales Agents will be paid a 3.0% commission and may act as agents or principals. Net proceeds are intended to fund research and clinical development (including ELI-002 programs), with remaining amounts for working capital and general corporate purposes. The prospectus supplement cites 17,800,307 shares outstanding as of December 31, 2025 and illustrates an example assuming $100,000,000 of sales at $12.20 per share.
Elicio Therapeutics is registering up to $400,000,000 of securities on a shelf to be sold from time to time, consisting of common stock, preferred stock, debt securities, warrants and units.
The pre-effective amendment updates the prospectus to incorporate the Company’s Annual Report on Form 10-K filed March 12, 2026, revises the Risk Factors and Experts sections, refreshes the corporate overview and forward-looking statements, and files the independent auditors’ consent as Exhibit 23.1. The prospectus states net proceeds will be used for working capital, research and development, business expansion, strategic transactions and general corporate purposes, with specific terms to be provided in prospectus supplements. The filing also notes recent clinical program context: the Phase 2 AMPLIFY-7P study of ELI-002 7P continued to final analysis after an IDMC interim review and the company anticipates a final disease-free survival analysis in the first half of 2026. The Company’s common stock traded at $12.90 on Nasdaq on March 10, 2026.
Elicio Therapeutics, Inc. files its annual report describing a clinical-stage oncology pipeline built on its lymph node–targeting Amphiphile (AMP) immunotherapy platform. The lead candidate, ELI-002 7P, targets seven common KRAS mutations in pancreatic and other solid tumors and is in a randomized Phase 2 PDAC trial.
Phase 1 data for ELI-002 2P and 7P showed high KRAS-specific T cell response rates, tumor biomarker declines, and encouraging relapse-free and overall survival signals. Elicio is also advancing preclinical AMP vaccines ELI-007 for BRAF-driven cancers and ELI-008 for TP53-mutant tumors, supported in part by research grants and an exclusive AMP license from MIT.
Elicio Therapeutics reported 2025 results and highlighted progress for its lead KRAS-targeted cancer immunotherapy ELI-002 7P. R&D expense fell to $24.9 million from $33.7 million in 2024 as its Phase 2 AMPLIFY-7P trial moved more patients into observation, while G&A rose to $12.8 million from $11.3 million. Net loss narrowed to $39.5 million, or $2.58 per share, from $51.9 million, or $4.25 per share. Cash and cash equivalents were $18.6 million as of December 31, 2025, up from $17.6 million a year earlier, helped by at-the-market equity proceeds of about $4.9 million in Q4 2025 and $6.3 million in Q1 2026 to date.
The company reiterated that its cash plus expected at-the-market proceeds are projected to fund operations into Q3 2026, beyond the anticipated event-driven primary disease-free survival analysis for the Phase 2 AMPLIFY-7P trial in the first half of 2026. Elicio reported fewer disease progressions and deaths than projected to date in this randomized study and plans to seek an End-of-Phase 2 meeting with the FDA, finalize a Phase 3 protocol, and advance ELI-002 7P toward a registrational trial in resected mKRAS pancreatic cancer, while exploring expansion into neoadjuvant, metastatic PDAC and other mKRAS-positive tumors.
Elicio Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (S-3/A) to delay the registration statement’s effective date by including the cover-page delaying amendment language.
The amendment states it does not modify the prospectus, includes an expenses table showing a SEC registration fee of $55,240.00 and a FINRA filing fee of $60,500.00, and describes indemnification provisions under Delaware law, the company’s charter and bylaws, director and officer indemnification agreements, a six-year indemnity/anti-amendment covenant tied to a Merger Agreement, and a six-year prepaid tail D&O policy.
Elicio Therapeutics, Inc. filed a shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units, to be sold from time to time February 27, 2026.
The prospectus describes that specific terms, pricing and offering methods will be set forth in future prospectus supplements; the company noted its common stock trades on Nasdaq at $11.74 per share as of February 26, 2026.
Elicio Therapeutics CEO Robert Connelly received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 73,600 restricted stock units of common stock at a price of $0, increasing his directly held common shares to 120,570.
He was also granted 147,200 stock options with an exercise price of $8.10 per share, all held directly. Both the RSUs and options vest 25% on February 2, 2027, with the remaining portions vesting over the following three years, contingent on his continued service to the company.
Elicio Therapeutics granted equity awards to its Chief Strategy and Financial Officer, Preetam Shah, on February 2, 2026. He received 24,000 restricted stock units, each representing one share of common stock at no cost on grant, and 47,900 stock options to buy common shares at an exercise price of $8.10 per share.
The RSUs vest 25% on February 2, 2027, with the rest vesting in annual installments over the following three years, contingent on continued service. The options vest 25% on February 2, 2027, with the remainder vesting in monthly installments over three years thereafter, also subject to continued service.